All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

RNA Sequencing Signatures May Guide Treatment Selection in Advanced ccRCC

October 18th 2025

RNAseq-defined clusters guided treatment selection in metastatic ccRCC in the phase 2 OPTIC trial, yielding a 76% ORR with cabozantinib plus nivolumab.

Fruquintinib Plus Sintilimab Improves PFS in Advanced RCC After First-Line VEGFR TKI Therapy

October 18th 2025

Fruquintinib plus sintilimab significantly extended progression-free survival in advanced RCC following first-line VEGFR TKI therapy.

Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

October 17th 2025

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Regorafenib Plus Nivolumab Yields Nonsuperior Survival in Refractory Gastric/GEJ Cancer

October 17th 2025

regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors

October 17th 2025

Osimertinib plus chemotherapy improved OS vs osimertinib alone in EGFR-mutated advanced non–small lung cancer, irrespective of poor prognostic factors.

SunRISe-4 Data Support Role for Neoadjuvant Gemcitabine Intravesical System Plus Cetrelimab in MIBC

October 17th 2025

SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.

Osimertinib Plus Local Consolidative Therapy Significantly Extends PFS in EGFR-Mutant NSCLC

October 17th 2025

NorthStar findings support osimertinib plus local consolidative therapy in EGFR-mutant non–small cell lung cancer.

Adjuvant Ribociclib Plus AI Therapy Has Long-Term Activity in HR+, HER2-Negative Early Breast Cancer

October 17th 2025

Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.

Durvalumab Plus FLOT Prolongs OS vs FLOT Alone in Gastric/GEJ Adenocarcinoma

October 17th 2025

The addition of durvalumab to FLOT prolonged overall survival vs FLOT alone in resectable gastric/gastroesophageal junction adenocarcinoma.

Sevabertinib Yields Robust Responses in HER2-Mutant Advanced NSCLC

October 17th 2025

Sevabertinib monotherapy led to robust and durable responses in first-line and pretreated patients with HER2-mutant advanced non–small cell lung cancer.

Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer

October 17th 2025

The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.

First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC

October 17th 2025

First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.

Combining Durvalumab With BCG Yields Significant DFS Benefit vs BCG Alone in BCG-Naive NMIBC

October 17th 2025

Durvalumab plus BCG induction and maintenance therapy yielded clinically meaningful improvement in DFS vs BCG induction and maintenance therapy alone in BCG-naive, high-risk NMIBC.

Zongertinib Displays Activity in Frontline HER2-Mutated NSCLC

October 17th 2025

Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.

Asciminib Receives Positive CHMP Opinion for Ph+ CP-CML

October 17th 2025

The EMA’s CHMP has recommended the approval of asciminib for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC

October 17th 2025

First-line treatment with lenvatinib, pembrolizumab, and chemotherapy did not improve OS vs chemoimmunotherapy in patients with advanced ESCC.

Adjuvant Cemiplimab Recommended for European Approval in CSCC

October 17th 2025

The EMA’s CHMP has recommended the approval of adjuvant cemiplimab in CSCC at high risk of recurrence after surgery and radiation

Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC

October 17th 2025

Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.

Mayo Clinic Researchers Discover ‘Traffic Controller’ Protein That Protects DNA, and May Help Kill Cancer Cells

October 17th 2025

Mayo Clinic researchers have identified a protein that acts like a traffic controller for DNA, preventing damage during cell division.

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL

October 16th 2025

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.